EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

miR-1247-3p regulation of CCND1 affects chemoresistance in colorectal cancer

Dequan Wang, Jielian Wang, Fei Yao, Zhufu Xie, Jianze Wu, Huiguang Chen, Qingming Wu iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0309979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Dequan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Institute of Infection, Immunology and Tumor Microenvironment, Schoo…. Hauptthemen laut MEDLINE: MicroRNAs, Cyclin D1, Colorectal Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effectiveness of chemotherapy involving 5-fluorouracil and cisplatin (DDP) for the treatment of colorectal cancer (CRC) is often limited due to the emergence of drug resistance. An increasing body of research highlights the crucial role of abnormally expressed microRNAs (miR/miRNAs) in fostering drug resistance in various types of cancer. The present study was the first to explore the potential roles and mechanisms of the small non-coding RNA miR-1247-3p in CRC, particularly its association with DDP resistance in CRC. The findings of the current study revealed a significant decrease in miR-1247-3p expression in CRC cells, especially those resistant to drugs. By contrast, there was a marked increase in the expression of cyclin D1 (CCND1), a known target gene of miR-1247-3p that is negatively regulated by this miRNA. By modulating CCND1, miR-1247-3p can effectively reduce drug resistance and promote apoptosis in CRC cells, suggesting that miR-1247-3p could potentially reduce chemotherapy resistance by targeting CCND1. These results highlight the pivotal role of miR-1247-3p in reducing chemotherapy resistance through the inhibition of CCND1, providing insight into a promising therapeutic strategy for overcoming CRC resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsCyclin D1Colorectal NeoplasmsDrug Resistance, NeoplasmCisplatinFluorouracilGene Expression Regulation, NeoplasticApoptosisHumansCell Line, TumorAntineoplastic Agents

Substanzen

MicroRNAsCyclin D1CCND1 protein, humanCisplatinFluorouracilMIRN1247 microRNA, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Institute of Infection, Immunology and Tumor Microenvironment, School of Medicine, Wuhan University of Science and Technology, Wuhan, Hube…
  • Department of Internal Medicine, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, China.
  • College of Health Medicine, China Three Gorges University, Yichang, Hubei, P.R. China.
  • Department of Gastroenterology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, China.

ORCID-Profile: Qingming Wu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, D., Wang, J., Yao, F., Xie, Z., Wu, J., Chen, H., & Wu, Q. (2024). miR-1247-3p regulation of CCND1 affects chemoresistance in colorectal cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0309979

Vancouver

Wang D, Wang J, Yao F, Xie Z, Wu J, Chen H, et al. miR-1247-3p regulation of CCND1 affects chemoresistance in colorectal cancer. PLOS ONE. 2024. doi:10.1371/journal.pone.0309979

BibTeX
@article{Wang2024,
  author = {Wang, Dequan and Wang, Jielian and Yao, Fei and Xie, Zhufu and Wu, Jianze and Chen, Huiguang and Wu, Qingming},
  title = {miR-1247-3p regulation of CCND1 affects chemoresistance in colorectal cancer},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0309979}
}
Kostenlos starten →